AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33891907
Drug: Full-dose anticoagulation
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose anticoagulation with rivaroxaban or enoxaparin
Trial: 33141770
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic antibiotic therapy
Trial: 32345383
Drug: New equation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New equation for estimating 24-h urinary Na excretion from casual spot urine specimen
Trial: 35022159
Drug: Third dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third dose of BNT162b2 vaccine
Trial: 37609358
Drug: High-dose subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose subcutaneous treprostinil
Trial: 37609358
Drug: Low-dose subcutaneous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose subcutaneous treprostinil
Trial: 33200489
Drug: Fosmetpantotenate (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosmetpantotenate (300 mg oral dose three times daily)
Trial: 32887379
Drug: Capsinoid (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsinoid (9 mg/day) for 6 weeks
Trial: 32887379
Drug: Capsinoid (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsinoid (9 mg/day) for 6 weeks in overweight subgroup
Trial: 32887379
Drug: Capsinoid (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsinoid (9 mg/day)
Trial: 35751657
Drug: Midostaurin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midostaurin with concomitant strong CYP3A4 inhibitors
Trial: 32389735
Drug: Gabapentin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (single dose preoperatively)
Trial: 32389735
Drug: Control (acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (acetaminophen and celecoxib alone)
Trial: 32772826
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg or 10 mg of melatonin
Trial: 33389304
Drug: Secret Agent
RxNorm normalized name: OCTINOXATE 7.5 g in 100 g / OXYBENZONE 6 g in 100 g / PADIMATE O 8 g in 100 g TOPICAL LIPSTICK [Phineas and Ferb Sun Smacker SPF 24 Secret Agent Strawberry]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secret Agent Society (SAS)
Trial: 32020185
Drug: TLR3 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLR3 and TNF treatment of human IECs.
Trial: 35060609
Drug: UMC+CC (Usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UMC+CC (Usual Medical Care plus Chiropractic Care)
Trial: 35060609
Drug: UMC+CC
RxNorm normalized name: XCEL-UMC-BETA
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UMC+CC
Trial: 36048042
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for 16 weeks
Trial: 33310502
Drug: Pharmacotherapy (monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy (monotherapy with selective serotonin reuptake inhibitors, SSRI, or selective serotonin noradrenalin reuptake inhibitors, SSNRI)
Trial: 32899492
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine intervention (250 mL of wine/day, 4 weeks)
Trial: 35317615
Drug: Ticagrelor +
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor + Aspirin
Trial: 37580610
Drug: Cytoreductive surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC)
Trial: 32706122
Drug: Botulinum neurotoxin
RxNorm normalized name: Botulinum neurotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum neurotoxin A (BoNT‐A) injections
Trial: 32960827
Drug: Oral glutathione
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glutathione (reduced glutathione) daily for 24 weeks
Trial: 33846983
Drug: Lidocaine/prilocaine cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine/prilocaine cream
Trial: 35675902
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no morphine)
Trial: 35186959
Drug: α-Lipoic acid
RxNorm normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-Lipoic acid (ALA) 1200 mg/d, intravenous infusion once daily plus standard care
Trial: 35186959
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care plus equal volume saline infusion (placebo)
Trial: 35107113
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g day-1 of GP seasoning
Trial: 35179770
Drug: Persian barley
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Persian barley water (PBW) 250 ml daily for two weeks
Trial: 34334656
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy (chemo ± radiation)
Trial: 32966959
Drug: Interpersonal Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal Therapy (IPT)
Trial: 39235772
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 8 weeks
Trial: 34464524
Drug: Mindfulness-Based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Cognitive Therapy for Preventing Suicide Behavior (MBCT-S)
Trial: 34464524
Drug: Enhanced treatment-as-usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment-as-usual (eTAU)
Trial: 32354590
Drug: Anesthetic cream
RxNorm normalized name: DIBUCAINE/DIPERODON ANESTHETIC CREAM
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthetic cream
Trial: 34430347
Drug: Cisplatin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (75 mg/m2) + pemetrexed (500 mg/m2) + bevacizumab (15 mg/kg) (CisPemBev)
Trial: 34430347
Drug: Carboplatin (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (AUC 6 mg/mL/min) + paclitaxel (200 mg/m2) + bevacizumab (15 mg/kg) (CarPacBev)
Trial: 35975917
Drug: OUD pharmacotherapy
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OUD pharmacotherapy
Trial: 35975917
Drug: Study medication
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study medication
Trial: 35975917
Drug: Study medication
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study medication duration
Trial: 35975917
Drug: Baseline sedative
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline sedative use
Trial: 33964907
Drug: Single 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 6 ml Hylan G-F 20 injection
Trial: 32326980
Drug: Smartphone-based digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone-based digital cognitive behavioural therapy (CBT) intervention
Trial: 34560012
Drug: All-trans retinoic
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans retinoic acid (10 mg orally twice daily for 12 weeks) plus high-dose dexamethasone (40 mg/day intravenously for 4 consecutive days)
Trial: 34560012
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone alone (40 mg/day intravenously for 4 consecutive days)
Trial: 35713247
Drug: PDRN treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDRN treatment (two consecutive injections of PDRN one and two days after surgery)
Trial: 35713247
Drug: PDRN treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDRN treatment
Trial: 34807494
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine (0.5 mg/kg bolus followed by 0.25 mg·kg−1·h−1 infusion)
Trial: 34807494
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (equivalent dose and regimen to ketamine)
Trial: 33487035
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose vitamin D supplementation
Trial: 32273054
Drug: Mineralocorticoid receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineralocorticoid receptor antagonists (MRAs)
Trial: 32676136
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (PMTA, PCEM, RCT)
Trial: 36295619
Drug: Laser micro-grooved
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser micro-grooved (LMG) platform switched implants and abutments (I&A)
Trial: 33500235
Drug: Shockwave therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shockwave therapy
Trial: 34403648
Drug: MgSO4 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MgSO4 (60 mg.kg‐1) with rocuronium 0.3 mg.kg‐1
Trial: 34403648
Drug: MgSO4 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MgSO4 (60 mg.kg‐1) with rocuronium 0.6 mg.kg‐1
Trial: 34403648
Drug: MgSO4 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MgSO4 (60 mg.kg‐1) with rocuronium 1.2 mg.kg‐1
Trial: 34403648
Drug: Control (saline)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (saline) with rocuronium 0.3 mg.kg‐1
Trial: 34403648
Drug: Control (saline)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (saline) with rocuronium 0.6 mg.kg‐1
Trial: 34403648
Drug: Control (saline)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (saline) with rocuronium 1.2 mg.kg‐1
Trial: 32981192
Drug: Days with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days with clinical hypoglycemia (54-69 mg/dL)
Trial: 32981192
Drug: Days with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days with clinically serious hypoglycemia (<54 mg/dL)
Trial: 35710444
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (STI screening and treatment and risk-reduction counseling without dPEP)
Trial: 33275326
Drug: Extended-release naltrexone
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naltrexone and bupropion (NB)
Trial: 35911215
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality serious game training program, twice a day for at least 10 days during hospitalization
Trial: 33838565
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral dose of 1 tablet containing 10 mg enalapril and 0.8 mg folic acid
Trial: 33838565
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral dose of 1 tablet containing 10 mg enalapril only
Trial: 37872497
Drug: Rituximab (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1000 mg)
Trial: 35967104
Drug: Atacicept 75
RxNorm normalized name: Atacicept
DrugBank: Atacicept (DB06399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atacicept 75 mg
Trial: 34185386
Drug: Neural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neural therapy (NT)
Trial: 35875898
Drug: Osteopathic Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic Medicine (OM)
Trial: 34006898
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NCT) with adriamycin and cyclophosphamide followed by docetaxel
Trial: 34006898
Drug: Neoadjuvant endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant endocrine therapy (NET) with goserelin and tamoxifen
Trial: 32460241
Drug: NZBC extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NZBC extract (600 mg/day for 7 days)
Trial: 32059692
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg PO bid
Trial: 32059692
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg PO bid plus dapagliflozin 10 mg PO qd
Trial: 33835174
Drug: Aprepitant (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant (125 mg orally 60 minutes before chemotherapy on day 1 and 80 mg orally each morning of days 2 and 3; palonosetron, 0.25 mg intravenously; dexamethasone, 6 mg orally 30 minutes before chemotherapy initiation on day 1)
Trial: 33835174
Drug: Placebo (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (125 mg orally 60 minutes before chemotherapy on day 1 and 80 mg orally each morning of days 2 and 3; palonosetron, 0.25 mg intravenously; dexamethasone, 12 mg orally 30 minutes before chemotherapy initiation on day 1)
Trial: 34476568
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (500 mg twice a day for 4 weeks)
Trial: 36052527
Drug: 60 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 days of head-down bed rest (HDBR) with daily multivitamin supplementation
Trial: 32039461
Drug: Adjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant treatment (radiation therapy) for early endometrial cancer
Trial: 34016037
Drug: Anabolic steroid
RxNorm normalized name: Anabolic steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anabolic steroid (Nandrolone Decanoate)
Trial: 33425079
Drug: Open-label placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label placebo (OLP) + treatment as usual (TAU)
Trial: 36522805
Drug: 3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/d pure EPA (ethyl ester, ≥97% purity) for 10 weeks
Trial: 36522805
Drug: 3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/d pure DHA (ethyl ester, ≥97% purity) for 10 weeks
Trial: 35030335
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus chemotherapy (360 mg nivolumab intravenously every 3 weeks plus oxaliplatin-based chemotherapy)
Trial: 35030335
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus chemotherapy (placebo plus oxaliplatin-based chemotherapy)
Trial: 38906161
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus chemotherapy
Trial: 35921605
Drug: LEN (Lenvatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEN (Lenvatinib monotherapy)
Trial: 34120160
Drug: S-methyl-L-thiocitrulline (SMTC)
RxNorm normalized name: methyl lactate, L-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-methyl-L-thiocitrulline (SMTC)
Trial: 35445439
Drug: 5-HT2 antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5-HT2 antagonist cyproheptadine
Trial: 37330257
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy for Seasonal Affective Disorder (CBT-SAD)
Trial: 37330257
Drug: Light Therapy
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light Therapy
Trial: 32472836
Drug: Blue light
RxNorm normalized name: Ocuvite Blue Light Mini Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blue light therapy
Trial: 33516141
Drug: Oral hydration
RxNorm normalized name: terpin hydrate Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydration (500 mL of water two hours before and 2000 mL during the 24 h after CE-CT)
Trial: 33516141
Drug: Intravenous hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydration (sodium bicarbonate 166 mmol/L 3 mL/kg/h starting one hour before and 1 mL/kg/h during the first hour after CE-CT)
Trial: 33516141
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral and intravenous hydration
Trial: 33835842
Drug: Trastuzumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab monotherapy (T)
Trial: 33835842
Drug: Trastuzumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab plus chemotherapy (T + C)
Trial: 36455006
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise (thrice weekly)
Trial: 36055919
Drug: Ipilimumab and
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab and Nivolumab (dual immunotherapy)
Trial: 33647189
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of ezetimibe/rosuvastatin 10/20 mg
Trial: 34844069
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment only (Control Group)
Trial: 32554072
Drug: LIFU-mediated gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: LIFU-mediated gene delivery to downregulate P2X3 receptor in carotid body (n=14)
Trial: 32554072
Drug: LIFU treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIFU treatment alone (n=4)
Trial: 32554072
Drug: Cationic microbubbles
RxNorm normalized name: Potassium cation
DrugBank: Potassium cation (DB01345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cationic microbubbles injection alone (n=4)
Trial: 34070014
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g whey protein gel (78 mL/368 kJ) consumed for four days
Trial: 32833606
Drug: Goal-Directed Therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-Directed Therapy
Trial: 33734131
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with rituximab
Trial: 36012027
Drug: 10 weekly
RxNorm normalized name: donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 weekly food education sessions based on the Transtheoretical model
Trial: 33929094
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of acute HIV infection (AHI) screening, contract partner notification, and social contact referral
Trial: 35782066
Drug: Routine physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine physical therapy with neuromobilization (Group 2)
Trial: 35782066
Drug: Routine physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine physical therapy without neuromobilization (Group 1)
Trial: 34571629
Drug: Vitrectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitrectomy with ILM peeling using heavy brilliant blue G (hBBG) staining
Trial: 32769416
Drug: Intensive Interdisciplinary
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive Interdisciplinary Pain Treatment (IIPT)
Trial: 32769416
Drug: Multimodal Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal Treatment (MMT)
Trial: 34314816
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of education on self-management and ergonomic principles, a prefabricated neoprene splint, hand exercises, and diclofenac sodium gel
Trial: 34464780
Drug: 3OHB infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3OHB infusion
Trial: 32187788
Drug: Advanced pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced pneumatic compression device (APCD), at-home Flexitouch head and neck APCD, used for at least 30 minutes daily
Trial: 34480861
Drug: Baricitinib (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib (4 mg once daily for up to 14 days)
Trial: 33853997
Drug: Thrombolysis for
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolysis for treatment of myocardial infarction
Trial: 33853997
Drug: Antithrombotic therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic therapy, lipid lowering, anti-diabetes, anti-obesity, heart failure treatments